Dihydromyricetin (DHM) for Alzheimer's Disease
Also known as: DHM, Ampelopsin, Ampelopsis grossedentata extract
DHM enhances GABAergic signaling and reduces neuroinflammation — targeting anxiety, sleep disturbance, and neurodegeneration in AD.
Mechanism of Action
DHM positively modulates GABA-A receptors without benzodiazepine-like sedation, reduces neuroinflammation through NLRP3 inflammasome suppression, inhibits amyloid-beta aggregation through direct binding, and activates AMPK/SIRT1 for metabolic neuroprotection.
General mechanism: Flavonoid. GABA-A positive modulator, AMPK/SIRT1 activator, NLRP3 inhibitor, PI3K/mTOR suppressor, hepatoprotective.
Current Evidence
Preclinical AD models show cognitive improvement and reduced pathology. GABA-A modulation improves sleep quality (sleep disruption worsens AD). Phase I studies for hangover/liver protection inform safety.
Clinical Status: Preclinical for AD. Phase I for liver protection. Available as supplement.
Safety Profile
Very safe. Well-tolerated. No significant side effects. Used traditionally in Chinese medicine.
Key Research Questions
- Can DHM's GABA modulation improve AD-related sleep and anxiety?
- Does DHM reduce amyloid pathology in human subjects?